UMSOM-Led Clinical Trial Using Focused Ultrasound with Chemotherapy Finds Potential Survival Benefit for Brain Cancer Patients
UMSOM-Led Clinical Trial Using Focused Ultrasound with Chemotherapy Finds Potential Survival Benefit for Brain Cancer Patients
Patients with the deadliest form of brain cancer, glioblastoma, who received MRI-guided focused ultrasound with standard-of-care chemotherapy had a nearly 40 percent increase in overall survival in a landmark trial of 34 patients led by University of Maryland School of Medicine (UMSOM) researchers. This is the first time researchers have demonstrated a potential survival benefit from using focused ultrasound to open the blood-brain barrier to improve delivery of chemotherapy to the tumor site in brain cancer patients after surgery.
Learn more about what these findings could mean for the future of brain cancer treatment and monitoring.
Photo: Graeme Woodworth, MD, professor and chair of neurosurgery at UMSOM and neurosurgeon-in-chief at the University of Maryland Medical Center, is principal investigator of the study.